



“Development of a novel blood-based diagnostic test for colorectal cancer”

ColoDetect

SME instrument – phase 2

Grant Agreement number: 666540

Deliverable 7.4

Informational ColoDetect factsheet

Due date of deliverable: 30-09-2016

Actual date of submission: 27-09-2016

Start date of project: 01-10-2015

Duration: 36 months

Name of partner responsible for deliverable: PROTEIN ALTERNATIVES SL

Authors: Juan Ignacio Imbaud

Project funded by the European Commission within H2020 Framework Programme		
Dissemination Level		
PU	Public, fully open, e.g. web	X
CI	Classified, information as referred to in Commission Decision 2001/844/EC	
RE	Restricted to a group specified by the consortium (including the Commission Services)	
CO	Confidential, restricted under conditions set out in Model Grant Agreement	

DISTRIBUTION LIST

Partner n°	INSTITUTION	PERSON IN CHARGE
1	PROTEIN ALTERNATIVES SL	Juan Ignacio Imbaud Project Coordinator jimbaud@proteinalternatives.com

INDEX

	Page
1. About the deliverable.....	4
2. About the factsheet	5
Annex I - Informational ColoDetect factsheet	7

1. About the deliverable

The present deliverable: **Informational ColoDetect factsheet** is part of the Task 7.2 named “*Production of dissemination materials and means*” in Work Package number 7 (WP7) of ColoDetect project, and is aimed at achieving the following objectives for the Dissemination & Communication of results [Months: 1-36]:

- dissemination and communication action to ensure a high impact and knowledge of the project.
- to allow i) the target final users of the *in vitro* diagnostic (IVD) kit in development and ii) the medical community in Europe to know about the specifications and application of the test.
- to promote the project in specific events aimed at the end-users of the project results.
- to create communication channels among ColoDetect, EU private and public health organizations related to the field of early detection of colorectal cancer (CRC).

ColoDetect project is aimed to contribute to enhance the present knowledge and competitiveness of EU institutions in the field of early detection of colorectal cancer by the commercialization of a new IVD kit.

2. About the factsheet

This informational factsheet is designed to provide elementary information on ColoDetect project. This project has received funding from the European's Union horizon 2020 research an innovation programme under grant agreement number 666540.

i. **Description**

This factsheet consist of two-pages. It has been printed with the same color pattern than the project website (<http://colodetect.com>) in blue and grey colors to preserve the same graphical design. It also shows a central picture which refers to the target population for ColoDetect test, the group of people ranging from 50 to 75 years old who will benefit from the results of the project in terms of survival and life quality. The picture is also exhibited in the main page of ColoDetect website

From a structural point of view, each page is divided in two columns by a blue line; the left side contains detailed information about ColoDetect project, while the right side is a summary of the project and contains information about its financial support by the European Commission.

The left side of ColoDetect factsheet starts with the tittle of the project:

NOVEL BLOOD-BASED DIAGNOSTIC TEST FOR COLORECTAL CANCER IN DEVELOPMENT
BY [PROTEIN ALTERNATIVES](#)

The following sections were defined:

[The challenge of early diagnosis of colorectal cancer](#)

This section is intended to be read by general public. It contains information about the epidemiology of colorectal cancer and the importance of an early diagnostic in order to achieve better rates of survival. It is written in simple language so that the message can be easily understood by the reader.

[COLODETECT project](#)

This section focus on ColoDetect project and explains the scientific background of the test. It is addressed to a more medical/scientific informed audience. It also compares ColoDetect with other current detection techniques and states its advantages.

[Detailed project steps](#)

The paragraph explains more in depth and with a technical language, the details of the project regarding the steps the project needs to overcome in order to obtain an *in vitro* diagnostic product. It is the roadmap of the project based on critical milestones.

Benefits for the population

It highlights the impact of the results of the project on the health of the population and the European healthcare systems and others in the world.

About PROALT

The last section refers to PROALT as beneficiary of this grant, and contains information about the company business activity and includes the logotypes of the subcontractors and their websites.

The right side starts with ColoDetect and European Commission logos, the date of edition followed by the phrase: *This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement number 666540*. This is focused in the commitment to promote the action according to the Grant Agreement clauses.

This right side of the sheet provides information on the project starting date, duration, total budget of the project, EU contribution or funding, the beneficiary of the grant and the project subcontracted partners. The back page presents in its right side key data with three bullets and contact information (Protein Alternatives postal address, email address and website).

ii. Dissemination

ColoDetect factsheet are intended to target the wide variety of stakeholders, healthcare sector, insurance companies, patients and health administration among others.

ColoDetect factsheet has been designed to be printed and also can be downloaded from the ColoDetect webpage. Factsheets will be disseminated throughout the term of the project and a number of 2.000 project factsheets has been printed according to D7.4.

The first event for its distribution has been BioSpain 2016 (Bilbao, 28th-30th September). BIOSPAIN is organized by ASEBIO, the Spanish Bioindustry Association. BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings (+3.300) and companies participating (+850). 34% of our delegates came from outside of Spain.

This factsheet will be also handed out at all events and meetings where PROALT will participate presenting ColoDetect results.

ANNEX I

Informational ColoDetect factsheet

NOVEL BLOOD-BASED DIAGNOSTIC TEST FOR COLORECTAL CANCER IN DEVELOPMENT BY PROTEIN ALTERNATIVES

The challenge of early diagnosis of colorectal cancer

Colorectal cancer (CRC) is the cancer of the colon or the rectum. Approximately 1.4 million people worldwide are diagnosed with CRC each year, therefore CRC is the most common cancer and its mortality rate is around 50% of affected people.

Despite these data, if the disease is detected at early stages, the treatment is often able to cure it completely, usually through surgical procedures. When colorectal cancer is found at early stages, many patients are cured after treatment and survival rates increase from 50 up to 90% (measured at 5 years), improving also the life quality of patients.

Therefore, the challenge of the diagnostic tests of CRC is to achieve the early detection of this devastating disease. Currently, only 30-40% of CRC cases are diagnosed in early stages because of the lack of reliable and easy-to-make diagnostic tests.



COLODETECT project

The objective of the project is the development and commercialization of a blood-based diagnostic test for early detection of CRC. The outlined test will detect simultaneously several antibodies present in the blood sample of a patient, generated by its own immune system against the tumor. These auto-antibodies appear at detectable levels in patient's blood before symptoms and allow the early diagnosis of the pathology.

The expected simplicity of COLODETECT test will allow the screening of large population at risk (people from 50-75 years). COLODETECT will also avoid the obvious limitations provided by the invasive detection techniques extensively used, as the colonoscopy, and will offer additional advantages compared to traditional CRC screening methods, such as the simplicity in use, detection accuracy and reduced cost.

COLODETECT

www.colodetect.com



Factsheet COLODETECT PROJECT SME Instrument phase 2

UPDATED: SEPTEMBER 2016

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement number 666540

Start date: October 2015

Duration: 36 months

Total budget: 2,5 M€

EU funding: 2,3 M€

Beneficiary:

Protein Alternatives

Subcontractors:

Azurebio
CSIC/CIB
INNOBIOCHIPS
IDIBAPS
Hospital Ramón y Cajal

Detailed project steps

The project has received funding from the European Union's Horizon 2020 SME Instrument under the grant agreement number 666540. It will run from October 1st, 2015 to September 30th, 2018.

The main objective of this project is to obtain a CRC diagnostic kit clinically validated and regulatory approved as an *in vitro* diagnostic product (IVD), and as well, to penetrate in the CRC diagnostic market.

- ✓ COLODETECT is based on analyzing a person's blood to detect simultaneously the presence of specific autoantibodies (biomarkers) against a reduced number of tumor antigens (8-10), using serum/plasma samples from CRC patients.
- ✓ COLODETECT will consist of a multiplexed immunoassay based on a standard Enzyme-linked immunoabsorbent assay (ELISA). The goal is to conjugate the simplicity of ELISA with the power of microarrays.
- ✓ The assay for the detection of CRC will be established and validated with clinical samples from different hospitals, and then tested for their marketability, to finally overtake the regulatory process and obtain the CE marking.

Benefits for the population

Colorectal cancer early detection programs are essential to decrease mortality around 30-35% and drastically reduce the treatment costs of people affected by the pathology, assuring the sustainability of the European healthcare systems and others in the world.

About PROALT



Protein Alternatives is the beneficiary of a grant from SME Instrument phase 2 of the Horizon 2020 programme to develop its project named COLODETECT. PROALT is a biotechnological company focused on the development and commercialization of biomarker-based assays for cancer diagnosis and clinical management.

Subcontractors: During COLODETECT project development, PROALT will collaborate with the following strategic partners:



www.cib.csic.es



www.innobiochips.fr



www.azurebio.com



www.idibaps.org



www.iryccis.org

PROALT also offers different products, as recombinant proteins or antibodies, and customized services (Contract Research Organization) related to protein design and antibodies generation, including their manufacturing and scaling up under non-GMP conditions.

Factsheet COLODETECT PROJECT UPDATED: SEPTEMBER 2016

COLODETECT



Keydata:

- ✓ The project has received funding from the European Union's Horizon 2020 SME Instrument, being a quality stamp and recognition of PROALT's research activity in cancer field and the innovations.
- ✓ The goal of the project is to develop a novel blood-based test for the early diagnosis of CRC and the screening of large populations at risk.
- ✓ Screening of populations with this test will achieve earlier detection of a greater number of patients, which will involve better treatment options to improve patient's survival and will reduce treatment costs.

Contact:

PROTEIN ALTERNATIVES (PROALT)

C/ Ronda de Poniente 16
Piso 1º A-F
28760 Tres Cantos
Madrid
SPAIN

info@proteinalternatives.com

www.proteinalternatives.com